Zinc Metallochaperones Reactivate Mutant p53 Using an ON/OFF Switch Mechanism: A New Paradigm in Cancer Therapeutics

PURPOSE: Zinc metallochaperones (ZMCs) are a new class of anti-cancer drugs that reactivate zinc deficient mutant p53 by raising and buffering intracellular zinc levels sufficiently to restore zinc binding. In vitro pharmacodynamics of ZMCs indicate that p53 mutant activity is ON by 4–6 hours and is...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:Clin Cancer Res
Main Authors: Yu, Xin, Kogan, Samuel, Chen, Ying, Tsang, Ashley T., Withers, Tracy, Lin, Hongxia, Gilleran, John, Buckley, Brian, Moore, Dirk, Bertino, Joseph, Chan, Chang, Kimball, S. David, Loh, Stewart N., Carpizo, Darren R.
Format: Artigo
Jezik:Inglês
Izdano: 2018
Teme:
Article
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC6139040/
https://ncbi.nlm.nih.gov/pubmed/29914895
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-18-0822
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki